References

Amalaradjou, M.A.R. en Bhunia, A.K. (2013) Bioengineered probiotics, a strategic approach to control enteric infections. Bioengineered 4, 379–387

Bailey, M.T. et al. (2011) Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. Brain. Behav. Immun. 25, 397–407

Belda-Ferre, P. et al. (2012) The oral metagenome in health and disease. ISME J.6, 46–56

Belda-Ferre, P. et al. (2015) The human oral metaproteome reveals potential biomarkers for caries disease. Proteomics 15, 3497–507.

Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership Plavix [package insert]. (2015) , 1–32

Bron, P. a. et al. (2011) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 10, 66–78

Buffie, C.G. et al. (2014) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–8

Candela, M. et al. (2010) Functional intestinal microbiome, new frontiers in prebiotic design. Int. J. Food Microbiol. 140, 93–101

Cardona, C. et al. (2016) Network-based metabolic analysis and microbial community modeling. Curr. Opin. Microbiol. 31, 124–131

Carmody, R.N. en Turnbaugh, P.J. (2014) Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J. Clin. Invest. 124, 4173–4181.

Chan, A.L.F. et al. (2018) Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study. Curr. Ther. Res. 69, 118–129

Clarke, G. et al. (2014) Minireview: Gut Microbiota: The Neglected Endocrine Organ. Mol. Endocrinol. 28, 1221–1238

Clayton, T.A. et al. (2019) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U. S. A. 106, 14728–14733

Davey, K.J. et al. (2013) Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.Transl. Psychiatry 3, e309

David, L.A. et al. (2013) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563

Dinan, T.G. et al. (2015) Collective unconscious: How gut microbes shape human behavior. J. Psychiatr. Res. 63, 1–9

Donaldson, G.P. et al. (2015) Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14, 20–32

Eckert, R. et al. (2006) Targeted killing of Streptococcus mutans by a pheromone-guided “smart” antimicrobial peptide. Antimicrob. Agents Chemother. 50, 3651–7

Edwards, I.R. en Aronson, J.K. (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356, 1255–1259

ElRakaiby, M. et al. (2014) Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 18, 402–14

Faust, K. et al. (2015) Metagenomics meets time series analysis: unraveling microbial community dynFaust, K., Lahti, L., Gonze, D., de Vos, W. M., & Raes,

Franzosa, E.A. et al. (2015) Identifying personal microbiomes using metagenomic codes. Proc. Natl. Acad. Sci. 112, E2930–E2938

Galley, J.D. et al. (2014) Maternal obesity is associated with alterations in the gut microbiome in toddlers. PLoS One 9,

Garber, K. (2015) Drugging the gut microbiome. Nat. Biotechnol. 33, 228–231

Garraway, L. A., Verweij, J., & Ballman, K. V. (2013). Precision oncology: an overview. J Clin Oncol, 31(15), 1803-5.

Gavrish, E. et al. Devices and methods for the selective isolation of microorganisms. . (2016) , Google Patents

Gerber, G.K. (2014) The dynamic microbiome. FEBS Lett. 588, 4131–4139.

Gilbert, J.A. et al. (2016) Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535, 94–103

Ginsburg, G.S. (2013) Realizing the opportunities of genomics in health care. JAMA 309, 1463–4

Guengerich, F.P. (2018) Cytochrome P450 and Chemical Toxicology. Chem. Res. Toxicol. 21, 70–83

Guo, L. et al. (2015) Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc. Natl. Acad. Sci. U. S. A. 112, 7569–7574

Haiser, H.J. en Turnbaugh, P.J. (2013) Developing a metagenomic view of xenobiotic metabolism. Pharmacol. Res. 69, 21–31

J. (2015). Metagenomics meets time series analysis: unraveling microbial community dynamics. Current Opinion in Microbiology. Curr. Opin. Microbiol.25, 56–66

Jeffery, I.B. et al. (2012) Categorization of the gut microbiota: enterotypes or gradients? Nat. Rev. Microbiol. 10, 591–2

Johnson, J.A. et al. (2012) Clopidogrel: a case for indication-specific,pharmacogenetics. Clin. Pharmacol. Ther. 91, 774–6.

Koskella, B. en Meaden, S. (2013) Understanding Bacteriophage Specificity in Natural Microbial Communities. Viruses 5, 806–823

Kutter, E. et al. (2010) Phage Therapy in Clinical Practice: Treatment of Human Infections. Curr. Pharm. Biotechnol. 11, 69–86

Lederberg, J. (2000). Infectious history. Science, 288(5464), 287-293.

Li, J. et al. (2016) Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc. Natl. Acad. Sci. U. S. A. 113, E1306-15

Lupski, J. R. (2010). Human genome at ten: The sequence explosion. Nature, 464(7289), 670-671.

Maurice, C.F. et al. (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152, 39–50

McCarthy, J. J., McLeod, H. L., & Ginsburg, G. S. (2013). Genomic medicine: a decade of successes, challenges, and opportunities. Science translational medicine, 5(189), 189sr4-189sr4.

Nobrega, F.L. et al. (2015) Revisiting phage therapy: new applications for old resources. Trends Microbiol. 23, 185–191

O’Keefe, S.J.D. et al. (2015) Fat, fibre and cancer risk in African Americans and rural Africans. Nat. Commun. 6, 6342

Petschow, B. et al. (2013) Probiotics, prebiotics, and the host microbiome: The science of translation. Ann. N. Y. Acad. Sci. 1306, 1–17

Preidis, G.A. en Versalovic, J. (2001) Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era. Gastroenterology 136, 2015–2031

R. Rizkallah, M. et al. (2012) The PharmacoMicrobiomics Portal: A Database for Drug-Microbiome Interactions. Curr. Pharmacogenomics Person. Med. 10, 195–203

Rautio, J. et al. (2018) Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255–270

Rowan, F. et al. (2010) Bacterial Colonization of Colonic Crypt Mucous Gel and Disease Activity in Ulcerative Colitis. Ann. Surg. 252, 869–875

Sampson, T.R. en Mazmanian, S.K. (2015) Control of Brain Development, Function, and Behavior by the Microbiome. Cell Host Microbe 17, 565–576

Sangwan, N. et al. (2016) Differential Functional Constraints Cause Strain-Level Endemism in Polynucleobacter Populations. mSystems 1, e00003-16

Schork, N. J. (2015). Personalized medicine: time for one-person trials. Nature, 520(7549), 609-611.

Sender, R. et al. (2016) Are We Really Vastly Outnumbered? Revisiting the Ratio  of Bacterial to Host Cells in Humans. Cell 164, 337–340

Shajib, M.S. en Khan, W.I. (2015) The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol. 213, 561–574

Sharpton, T.J. (2014) An introduction to the analysis of shotgun metagenomic data. Front. Plant Sci. 5, 209

Sousa, T. et al. (2018) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1–25

Strandwitz, P. et al. GABA-Modulating Bacteria : Microbiome-Based Therapeutics for Depression? , RISE. (2015)

Sultana, J. et al. (2013) Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother. 4, 73

Summers, W.C. (2012) The strange history of phage therapy. Bacteriophage 2, 130–133

Surana, N.K. en Kasper, D.L. (2014) Deciphering the tete-a-tete between the microbiota and the immune system. J. Clin. Invest. 124, 4197–4203

Swanson, H.I. (2015) Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry? Drug Metab. Dispos. 43, 1499–1504.

Thomas, T. et al. (2012) Metagenomics - a guide from sampling to data analysis. Microb. Inform. Exp. 2, 3

Thompson, B.M. en Boiani, J. (2015) The Legal Environment for Precision Medicine. Clin. Pharmacol. Ther. [Accepted, 167–169

Verbeurgt, P. et al. (2014) How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9 , CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 15, 655–665

Viaud, S. et al. (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–6

Wallace, B.D. en Redinbo, M.R. (2013) The human microbiome is a source of therapeutic drug targets. Curr. Opin. Chem. Biol. 17, 379–384

Wang, Z. et al. (2015) Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 163, 1585–1595

Watkins, P.B. et al. (2016) Aminotransferase Elevations in Healthy Adults Receiving 4 Grams of Acetaminophen Daily. JAMA 296, 87

Wilson, I.D. en Nicholson, J.K. (2015) The Modulation of Drug Efficacy and Toxicity by the Gut Microbiome. bll 323–341

Yao, J. et al. (2016) A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome. Antimicrob. Agents Chemother. DOI: 10.1128/AAC.00535-16